VERMOX ® is a drug based on Mebendazole
THERAPEUTIC GROUP: Pesticide
Indications VERMOX ® Mebendazole
VERMOX ® is a broad spectrum antiparasitic drug used in the treatment of infections caused by roundworms, pinworms, whipworms, hookworms, strongyloids and tapeworms.
Mechanism of action VERMOX ® Mebendazole
VERMOX ® is a medicinal specialty, widely used in the clinical setting, especially in the treatment of pinworm infestations, based on Mebendazole, an active ingredient with a broad spectrum of action directed towards the main intestinal parasites in humans.
Thanks to the low systemic absorption that characterizes it, useful both in limiting the potential systemic effects of the drug and in "optimizing" intestinal activity, Mebendazole actively carries out its biological function by binding the parasite's tubulin and preventing the polymerization of microtubules.
These ultrastructural modifications can also affect the normal metabolic activities of the parasite, which, not being able to effectively capture glucose, undergoes a series of energy alterations such as to seriously compromise its vital capacities up to inducing its death through autolytic processes.
What remains of the parasite will be eliminated in the faeces together with the drug, while the small amount absorbed by the gastrointestinal mucosa following a first pass metabolism can be rapidly excreted.
Studies carried out and clinical efficacy
MEBENDAZOLO AND GARDENS
World J Gastroenterol. 2006 Oct 21; 12: 6366-70.
Randomized clinical study of five days apostrophe therapy with mebendazolecompared to quinacrine in the treatment of symptomatic giardiasis in children.
Canete R, Escobedo AA, Gonzalez ME, Almirall P.
Study that demonstrates the efficacy of Mebendazole in the treatment of Giardiasis in patients aged between 5 and 15 years, without further improvements deriving from more intense therapies than those classically used.
MEBENDAZOLO AND ALBENDAZOLO IN THE TREATMENT OF TENIASIS
PLoS One. 2011; 6: e25003.
Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp .: a randomized controlled trial.
Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN.
Clinical trial that reaffirms the efficacy of Mebendazole, at high doses, in the treatment of teniasis and intestinal parasites, while describing the greater efficacy of other more recent pesticides such as Albendazole.
MEBENDAZOLO AND PREGNANCY
Congenit Anom (Kyoto). 2005 Sep; 45: 85-8.
Population-based case-control study of mebendazole in pregnant women for birth outcomes.
Acs N, Bánhidy F, Puhó E, Czeizel AE.
Clinical trial conducted only on a modest number of patients, which did not identify a teratogenic and foetotoxic potential of Mebendazole for the embryo or fetus. Despite the result, the same authors do not exclude these activities given the low number of patients examined.
Method of use and dosage
VERMOX ®
Oral tablets of 100 mg - 500 mg of Mebendazole;
Oral suspension of 20 mg of Mebendazole per ml of solution.
The dosage, the pharmaceutical form and the duration of therapy must be defined by your doctor based on the physio-pathological conditions of the patient, the severity of the clinical picture and above all based on the type of parasite responsible for the pathology.
In principle, the therapy is always of short duration, generally of a few days, and characterized by dosages between 100 and 500 mg per day.
Warnings VERMOX ® Mebendazole
Therapy with VERMOX ® should be preceded by a careful medical examination aimed at evaluating the prescribing appropriateness of Mebendazole and the possible presence of contraindications to the use of the drug.
In addition to drug therapy, the patient, under specific medical advice, should also apply all the hygiene rules useful for limiting the spread of the parasite in the environment.
Rarely and especially in children under one year of age, hypersensitivity reactions, sometimes even severe, have been documented.
It is also important to remember that this drug is not effective against cysticercosis.
PREGNANCY AND BREASTFEEDING
The teratogenic and mutagenic potential of Mebendazole, observed on experimental models, extends the aforementioned contraindications to the use of VERMOX ® also to pregnancy and the subsequent breastfeeding period.
Interactions
The intense first pass metabolism to which the small amount of Mebendazole absorbed by the intestinal mucosa is subjected could be compromised by the simultaneous intake of active ingredients with inhibitory action such as cimetidine, thus inducing an increase in the blood concentrations of the drug.
The presence of case-control studies, in which the onset of severe dermatolytic reactions is reported, imposes a ban on the simultaneous intake of Mebendazole and Metronidazole.
Contraindications VERMOX ® Mebendazole
The use of VERMOX ® is contraindicated in case of hypersensitivity to the active principle or to one of its excipients.
Undesirable Effects - Side Effects
Therapy with Mebendazole could cause the onset of adverse reactions, fortunately rare, affecting the gastrointestinal tract with diarrhea, abdominal pain, nausea and vomiting.
The reactions affecting the haematopoietic apparatus or those linked to hypersensitivity are decidedly rarer.
Note
VERMOX ® is a drug subject to mandatory medical prescription.
The information on VERMOX ® Mebendazole published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
